A5014807805- Prostate Cancer Treatment and Research
- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Prostate Cancer Diagnosis and Treatment
- Heat shock proteins research
- Molecular Biology Techniques and Applications
- Neuroblastoma Research and Treatments
- Cancer, Hypoxia, and Metabolism
- PARP inhibition in cancer therapy
- Cancer-related gene regulation
- Cellular Mechanics and Interactions
- RNA modifications and cancer
- Nanowire Synthesis and Applications
- Skin and Cellular Biology Research
- Nanoplatforms for cancer theranostics
- Additive Manufacturing and 3D Printing Technologies
- Ubiquitin and proteasome pathways
- Chemokine receptors and signaling
- Bioinformatics and Genomic Networks
- Micro and Nano Robotics
- Reproductive tract infections research
- Endoplasmic Reticulum Stress and Disease
- 3D Printing in Biomedical Research
- Circular RNAs in diseases
- Advanced Proteomics Techniques and Applications
Stanford University
2020-2024
University of California, Los Angeles
2023-2024
Palo Alto University
2021-2024
APLA Health
2024
Neuroendocrine carcinomas, such as neuroendocrine prostate cancer and small-cell lung cancer, commonly have a poor prognosis limited therapeutic options. We report that ubiquitin carboxy-terminal hydrolase L1 (UCHL1), deubiquitinating enzyme, is elevated in tissues plasma from patients with carcinomas. Loss of UCHL1 decreases tumor growth inhibits metastasis these malignancies. maintains differentiation promotes progression by regulating nucleoporin, POM121, p53. binds, deubiquitinates,...
Significance NEPC is a highly aggressive subtype of prostate cancer that increasing in incidence, likely due to use new secondary androgen deprivation therapies. Here, we demonstrate Trop2 significantly elevated CRPC and represents driver metastatic NEPC. overexpression increases tumor growth, drives metastasis neuroendocrine phenotype, PARP1 levels. Inhibition Trop2-driven decreases features, colonization vivo, suggesting inhibitors may represent promising therapeutic strategy for...
Abstract Biohybrid microrobotics are exploited as a delivery approach to actively transport therapeutic payload tumors. However, the utility of this can be diminished by tumor hypoxia. Moreover, current biohybrid design is mainly focused on living organisms’ motility and biocompatibility, yet unique biological function natural organism often overlooked. Here, an all‐in‐one self‐propelled volvox‐based multifunctional robot, that is, Volbot, with built‐in capabilities fluid mixing, multimode...
CAR (chimeric antigen receptor) T cell therapy has shown clinical success in treating hematological malignancies, but its treatment of solid tumors been limited. One major challenge is on-target, off-tumor toxicity, where cells also damage normal tissues that express the targeted antigen. To reduce this detrimental side-effect, Boolean-logic gates like AND-NOT have utilized an inhibitory (iCAR) to specifically curb activity at selected nonmalignant tissue sites. However, strategy seems...
Abstract Breast cancer remains the second most lethal among women in United States and triple-negative breast is aggressive subtype with limited treatment options. Trop2, a cell membrane glycoprotein, overexpressed almost all epithelial cancers. In this study, we demonstrate that Trop2 (TNBC), downregulation of delays TNBC tumor growth supporting oncogenic role cancer. Through proteomic profiling, discovered metabolic signature comprised TALDO1, GPI, LDHA, SHMT2, ADK proteins were...
Among men, prostate cancer is the second leading cause of cancer-associated mortality, with advanced disease remaining a major clinical challenge. We describe small molecule, SU086, as therapeutic strategy for cancer. demonstrate that SU086 inhibits growth cells in vitro, cell-line and patient-derived xenografts vivo, ex vivo patient specimens. Furthermore, combination standard care second-generation anti-androgen therapies displays increased impairment cell tumor vitro vivo. Cellular...
Abstract Distinguishing indolent from clinically significant localized prostate cancer is a major clinical challenge and influences decision-making between treatment active surveillance. The development of novel predictive biomarkers will help with risk stratification, decision-making, leading to decrease in over or under-treatment patients cancer. Here, we report that Trop2 prognostic tissue biomarker for by utilizing the Canary Prostate Cancer Tissue Microarray (CPCTA) cohort composed 1100...
ABSTRACT Extracellular vesicles (EVs) are lipid nano-to-micro-sized increasingly identified as valuable liquid biopsy tools for medical applications. However, the heterogeneity of cargo and lack convenient quantification methods to characterize EVs pose challenges in identifying with specific markers. In this study, we show isolation, characterization, detection, a cancer-specific marker, Trop2, on circulating extracellular serum (EV-Trop2). This work combines unique advantages our...
Abstract Metastasis is the main cause of cancer-associated morbidity which will account for ∼ 600,000 deaths in USA 2021. Defining new mechanisms that drive cancer metastasis vital developing therapeutic strategies and improving clinical outcomes patients. Herein, we describe a recently established 3D Matrigel drop invasion assay to measure cell migration capability vitro. This versatile simple tool test ability cells invade migrate, functional role genes interest migration, analyze...
Abstract Prostate cancer remains the most common non-cutaneous malignancy among men in United States. To discover potential serum-based biomarkers for high-risk prostate cancer, we performed a high-multiplex immunoassay utilizing patient-matched pre-operative and post-operative serum samples from ten with high-grade high-volume cancer. Our study identified six (CASP8, MSLN, FGFBP1, ICOSLG, TIE2 S100A4) out of 174 proteins that were significantly decreased after radical prostatectomy. High...
Abstract Background Distinguishing men with aggressive from indolent prostate cancer is critical to decisions in the management of clinically localized cancer. Molecular signatures disease could help overcome this major clinical challenge by reducing unnecessary treatment and allowing more appropriate disease. Methods We performed a mass spectrometry‐based proteomic analysis normal malignant tissues 22 who underwent surgery for Prostate samples included Grade Groups (3–5), 8 patients...
Abstract Background Neuroendocrine phenotype is commonly associated with therapy resistance and poor prognoses in small-cell neuroendocrine cancers (SCNCs), such as prostate cancer (NEPC) lung (SCLC). Expression levels of current markers exhibit high case-by-case variability, so multiple are used combination to identify SCNCs. Here, we report that ACAA2 elevated SCNCs a potential molecular indicator for Methods expressions tumour xenografts, tissue microarrays (TMAs), patient tissues from...
Glandular cancers are amongst the most prevalent types of cancer, which can develop in many different organs, presenting challenges their detection as well high treatment variability and failure rates. For that purpose, anticancer drugs commonly tested cancer cell lines grown 2D tissue culture on plastic dishesin vitro, or animal modelsin vivo. However, models diverge significantly from 3D characteristics living tissues require extensive use time. cancers, such prostate cancer-the second...
Abstract Neuroendocrine carcinomas, such as neuroendocrine prostate cancer (NEPC), small cell lung (SCLC), and neuroblastoma, share common histological features, including expression of markers, rapid relapse after treatment, poor prognosis. Due to the clinical outcome patients with there is a critical need identify new drivers, therapeutic targets, effective strategies for these malignancies. Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) protease that has dual function in regulating...
Abstract The G-protein-coupled chemokine receptor (GPCR), CXCR4, is ubiquitously expressed in malignant tumor tissues, and controls migration other survival mechanisms upon interaction with its agonist, stromal cell-derived 1α (SDF1α). CXCR4/SDF1α axis relevant to shaping the microenvironment mainly metastatic spread of primary tumors distal organs immune response; thus, expression CXCR4 vital aggressiveness, probability, metastasis-associated mortality. signals through a homodimer, but also...
Abstract Prostate cancer is estimated to contribute over 34,000 deaths in men residing the United States, with majority fatality due metastatic disease. CDC7 a kinase that regulates DNA replication and an emerging biomarker for poor prognosis carcinomas such as Wilms tumor hepatocellular carcinomas. In this study, we demonstrated high level of associated prostate when compared benign tissues or localized cancer. Furthermore, found expression highest patient-derived xenografts (PDX) models...
Prostate cancer is the second leading cause of cancer-related deaths among men worldwide. With heavy androgen deprivation therapies, prostate may shift to receptor negative and neuroendocrine subtype castration resistant cancer, defined as double-negative cancer. Double-negative associated with poor prognosis disease mortality. The molecular mechanisms underlying emergence remain poorly understood. Here, we demonstrate that Ubiquitin C-Terminal Hydrolase L1 (UCH-L1), negatively correlated...
Among men, prostate cancer is the second leading cause of cancer-associated mortality, with advanced disease remaining a major clinical challenge. We describe small molecule, SU086, as new therapeutic strategy for cancer. demonstrate that SU086 inhibits growth cells in vitro, cell line and patient-derived xenografts vivo, ex vivo patient specimens. Furthermore, combination standard care second-generation anti-androgen therapies displayed increased impairment tumor vitro vivo. Cellular...
Abstract Introduction and Objectives: Breast cancer remains the second most lethal among women in US, with triple negative breast (TNBC) as aggressive subtype limited treatment options. Trop2, a cell membrane glycoprotein, is overexpressed nearly all epithelial cancers including cancer. In this study, we demonstrate that loss of Trop2 derives downregulation metabolic genes. oncogene-driven gene signature highly elevated patients predicts poor outcome. Methods: expression levels two...